PH30153A - (S)-(+) hydroxychloroquine - Google Patents

(S)-(+) hydroxychloroquine

Info

Publication number
PH30153A
PH30153A PH46684A PH46684A PH30153A PH 30153 A PH30153 A PH 30153A PH 46684 A PH46684 A PH 46684A PH 46684 A PH46684 A PH 46684A PH 30153 A PH30153 A PH 30153A
Authority
PH
Philippines
Prior art keywords
hydroxychloroquine
treatment
malaria
medicament
diseases
Prior art date
Application number
PH46684A
Other languages
English (en)
Inventor
Vera J Stetcher
William F Michne
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of PH30153A publication Critical patent/PH30153A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/46Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
PH46684A 1992-09-15 1993-08-13 (S)-(+) hydroxychloroquine PH30153A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/945,032 US5314894A (en) 1992-09-15 1992-09-15 (S)-(+)-hydroxychloroquine

Publications (1)

Publication Number Publication Date
PH30153A true PH30153A (en) 1997-01-21

Family

ID=25482508

Family Applications (1)

Application Number Title Priority Date Filing Date
PH46684A PH30153A (en) 1992-09-15 1993-08-13 (S)-(+) hydroxychloroquine

Country Status (18)

Country Link
US (1) US5314894A (ja)
EP (1) EP0588430B1 (ja)
JP (1) JPH06199801A (ja)
KR (1) KR940007002A (ja)
AT (1) ATE166646T1 (ja)
AU (2) AU4732693A (ja)
CA (1) CA2104903A1 (ja)
CZ (1) CZ192393A3 (ja)
DE (1) DE69318783D1 (ja)
FI (1) FI934051L (ja)
HU (1) HUT70025A (ja)
IL (1) IL107004A0 (ja)
MX (1) MX9305621A (ja)
MY (1) MY109822A (ja)
NO (1) NO180677C (ja)
NZ (1) NZ248671A (ja)
PH (1) PH30153A (ja)
SK (1) SK98793A3 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2005062723A2 (en) * 2003-11-24 2005-07-14 Ipca Laboratories Limited An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates
KR101115412B1 (ko) * 2008-09-08 2012-06-12 주식회사 대희화학 하이드록시클로로퀸의 신규 제조방법
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するc型肝炎ウイルス関連疾患の処置
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN105693606B (zh) * 2016-03-09 2017-12-05 西安科技大学 一种光学纯(r)/(s)‑羟氯喹的不对称合成方法
CN105693605B (zh) * 2016-03-09 2017-12-22 西安科技大学 一种光学纯(r)/(s)‑氯喹的不对称合成方法
CN110283121A (zh) * 2019-08-06 2019-09-27 华东理工大学 羟氯喹的合成方法
CN113350343A (zh) * 2020-03-06 2021-09-07 华南理工大学 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN113350344A (zh) * 2020-03-06 2021-09-07 华南理工大学 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
EP4135673A4 (en) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE
US20230139565A1 (en) * 2020-04-20 2023-05-04 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
US20210369699A1 (en) 2020-05-31 2021-12-02 Genovate Biotechnology Co. Ltd. Treatment of lupus erythematosus using s-hydroxychloroquine
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111803501B (zh) * 2020-06-17 2022-10-18 南方科技大学 手性氯喹羟氯喹作为降低心脏毒性的用途
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯(深圳)科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112505198A (zh) * 2020-12-29 2021-03-16 珠海润都制药股份有限公司 一种s-硫酸羟氯喹异构体检验方法
CN117396204A (zh) * 2021-06-04 2024-01-12 健亚生物科技股份有限公司 使用s-羟氯喹治疗抗磷脂综合征
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN115089584A (zh) * 2022-06-14 2022-09-23 广州惠善医疗技术有限公司 手性羟氯喹或其药学上可接受的盐在制备防诊治免疫疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) * 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives

Also Published As

Publication number Publication date
JPH06199801A (ja) 1994-07-19
AU4732693A (en) 1994-03-24
NO180677B (no) 1997-02-17
EP0588430A1 (en) 1994-03-23
FI934051A7 (fi) 1994-03-16
MY109822A (en) 1997-08-30
NO933293L (no) 1994-03-16
HUT70025A (en) 1995-09-28
FI934051A0 (fi) 1993-09-15
NO180677C (no) 1997-05-28
KR940007002A (ko) 1994-04-26
HU9302613D0 (en) 1993-12-28
FI934051L (fi) 1994-03-16
US5314894A (en) 1994-05-24
SK98793A3 (en) 1994-09-07
NO933293D0 (no) 1993-09-15
CZ192393A3 (en) 1994-03-16
MX9305621A (es) 1994-03-31
ATE166646T1 (de) 1998-06-15
CA2104903A1 (en) 1994-03-16
IL107004A0 (en) 1993-12-28
NZ248671A (en) 1995-04-27
AU7549496A (en) 1997-04-10
EP0588430B1 (en) 1998-05-27
DE69318783D1 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
PH30153A (en) (S)-(+) hydroxychloroquine
GB2206788B (en) 5 ht-3 antagonist for the treatment or reduction of dependence
GR3007251T3 (ja)
HU0301425D0 (en) K-252a-derivatives and pharmaceutical composition containing thereof
AU6905391A (en) Methods and compositions for the treatment of hodgkin's disease
EP0331620A3 (en) Agent for the treatment of parkinson's disease
IL111239A0 (en) Substituted 1-naphthyl-3-pyrazolecarboxamides, their preparation and pharmaceutical compositions containing them
OA09194A (en) "Insecticidal treatment and compositions therefor".
IL103478A0 (en) Therapeutic agent
CA2002483A1 (en) Fluoxetine analog
ZA9410098B (en) Methods of inhibiting Turner's Syndrome
IL99077A0 (en) New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
IL90499A0 (en) Therapeutic uses of 2',5'-oligoadenylates
ZA931079B (en) Topical use of local anaesthetic agents for rheumatoid arthritis as well as a pharmaceutical preparation and a method for the treatment thereof
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU1807592A (en) New combination preparation for treatment of parkinson's disease
IL101482A0 (en) Substituted 2',3'-dideoxy-5-trifluoromethyluridines,and pharmaceutical compositions containing them
GR3015469T3 (en) 5,11-dihydro-6H-pyrido[2,3,-b][1,4]benzodiazepin-6-ones and -thiones and their use in the prevention or treatment of AIDS.
RU93052163A (ru) (s) - (+) - гидроксихлорохин и композиция для лечения
IL104756A0 (en) Composition for the treatment of glaucoma
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
EP0796105A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES COMPRISING THE B OLIGOMER OF PERTUSSIS TOXIN OR ITS SUB-UNITS
AU6955294A (en) Agents for the prevention and treatment of parkinson's disease
World Health Organization Dictionary of ophthalmology
Greer Effects of NaCl on tobacco callus cultures